Logo image of RLYB

RALLYBIO CORP (RLYB) Stock Price, Quote, News and Overview

NASDAQ:RLYB - Nasdaq - US75120L1008 - Common Stock - Currency: USD

0.4062  +0.01 (+2.58%)

Premarket: 0.386 -0.02 (-4.97%)

RLYB Quote, Performance and Key Statistics

RALLYBIO CORP

NASDAQ:RLYB (7/11/2025, 8:00:02 PM)

Premarket: 0.386 -0.02 (-4.97%)

0.4062

+0.01 (+2.58%)

Sector
GICS SectorHealth Care
GICS IndustryBiotechnology
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS SubIndustryBiotechnology
Statistics
52 Week High1.54
52 Week Low0.22
Market Cap16.90M
Shares41.61M
Float36.86M
Yearly DividendN/A
Dividend YieldN/A
PEN/A
Fwd PEN/A
Earnings (Next)08-06 2025-08-06/bmo
IPO07-29 2021-07-29


RLYB short term performance overview.The bars show the price performance of RLYB in the last week, last 2 weeks, last month, last 3 and 6 months. 1 week 2 week 1 month 3 months 6 months 0 20 -20 40 -40 60

RLYB long term performance overview.The bars show the price performance of RLYB in the last 1, 2 and 3 years. 1 year 2 years 3 years -20 -40 -60 -80

The current stock price of RLYB is 0.4062 USD. In the past month the price increased by 14.04%. In the past year, price decreased by -70.57%.

RALLYBIO CORP / RLYB Daily stock chart

RLYB Competitors/Peers

The largest stocks on the US markets in the "Biotechnology" sub-industry
Full List
Symbol
Company Name
TA
FA
PE
Market Cap
ABBV ABBVIE INC 18.74 339.94B
AMGN AMGEN INC 14.22 158.77B
GILD GILEAD SCIENCES INC 14.17 136.38B
VRTX VERTEX PHARMACEUTICALS INC N/A 120.40B
REGN REGENERON PHARMACEUTICALS 12.81 61.30B
ALNY ALNYLAM PHARMACEUTICALS INC N/A 41.07B
ARGX ARGENX SE - ADR 97.43 34.21B
BNTX BIONTECH SE-ADR N/A 27.14B
ONC BEONE MEDICINES LTD-ADR 6.39 27.09B
NTRA NATERA INC N/A 21.91B
BIIB BIOGEN INC 8.48 19.67B
INSM INSMED INC N/A 18.63B

About RLYB

Company Profile

RLYB logo image Rallybio Corp. engages in the identification, research and development, and manufacture of clinical biotechnology products and therapies for severe and rare diseases. The company is headquartered in New Haven, Connecticut and currently employs 25 full-time employees. The company went IPO on 2021-07-29. The company has a pipeline of product candidates aimed at addressing diseases with unmet medical needs in the areas of maternal fetal health, complement dysregulation, hematology, and metabolic disorders. The company has two clinical-stage programs: RLYB212, an anti-HPA-1a antibody for the prevention of fetal and neonatal alloimmune thrombocytopenia (FNAIT) and RLYB116, an inhibitor of complement component 5 (C5), with the potential to treat several diseases of complement dysregulation, as well as additional programs in preclinical development. Its other product candidates include RLYB114, is a C5-targeted Affibody molecule conjugated to polyethylene glycol; RLYB332, is a preclinical antibody designed to inhibit MTP-2, and REV102 Program, is a small molecule inhibitor of ectonucleotide pyrophosphatase/ phosphodiesterase 1(ENPP1).

Company Info

RALLYBIO CORP

234 Church Street, Suite 1020

New Haven CONNECTICUT US

CEO: Martin W. Mackay

Employees: 25

RLYB Company Website

RLYB Investor Relations

Phone: 12038593820

RALLYBIO CORP / RLYB FAQ

What is the stock price of RALLYBIO CORP today?

The current stock price of RLYB is 0.4062 USD. The price increased by 2.58% in the last trading session.


What is the ticker symbol for RALLYBIO CORP stock?

The exchange symbol of RALLYBIO CORP is RLYB and it is listed on the Nasdaq exchange.


On which exchange is RLYB stock listed?

RLYB stock is listed on the Nasdaq exchange.


What is the price forecast or stock price prediction for RALLYBIO CORP stock?

11 analysts have analysed RLYB and the average price target is 1.02 USD. This implies a price increase of 151.11% is expected in the next year compared to the current price of 0.4062. Check the RALLYBIO CORP stock analysts ratings, price target forecast and up-and down grades for more detailed information.


What is RALLYBIO CORP worth?

RALLYBIO CORP (RLYB) has a market capitalization of 16.90M USD. This makes RLYB a Nano Cap stock.


How many employees does RALLYBIO CORP have?

RALLYBIO CORP (RLYB) currently has 25 employees.


What are the support and resistance levels for RALLYBIO CORP (RLYB) stock?

RALLYBIO CORP (RLYB) has a support level at 0.33 and a resistance level at 0.5. Check the full technical report for a detailed analysis of RLYB support and resistance levels.


Is RALLYBIO CORP (RLYB) expected to grow?

The Revenue of RALLYBIO CORP (RLYB) is expected to decline by -69.46% in the next year. Check the estimates tab for more information on the RLYB EPS, Sales, EBIT and EBITDA future analyst estimates.


Should I buy RALLYBIO CORP (RLYB) stock?

There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:


Does RALLYBIO CORP (RLYB) stock pay dividends?

RLYB does not pay a dividend.


When does RALLYBIO CORP (RLYB) report earnings?

RALLYBIO CORP (RLYB) will report earnings on 2025-08-06, before the market open.


What is the Price/Earnings (PE) ratio of RALLYBIO CORP (RLYB)?

RALLYBIO CORP (RLYB) does not have a PE ratio as the earnings reported over the last twelve months were negative (-1.09).


What is the Short Interest ratio of RALLYBIO CORP (RLYB) stock?

The outstanding short interest for RALLYBIO CORP (RLYB) is 0.9% of its float. Check the ownership tab for more information on the RLYB short interest.


RLYB Technical Analysis

ChartMill assigns a technical rating of 4 / 10 to RLYB. When comparing the yearly performance of all stocks, RLYB is a bad performer in the overall market: 80.22% of all stocks are doing better.


Chartmill TA Rating
Chartmill Setup Rating

RLYB Fundamental Analysis

ChartMill assigns a fundamental rating of 3 / 10 to RLYB. While RLYB has a great health rating, there are worries on its profitability.


Chartmill FA Analysis
Valuation
Growth
Profitability
Health
Dividend

RLYB Financial Highlights

Over the last trailing twelve months RLYB reported a non-GAAP Earnings per Share(EPS) of -1.09. The EPS increased by 42.02% compared to the year before.


Industry RankSector Rank
PM (TTM) N/A
ROA -83.1%
ROE -89.11%
Debt/Equity 0
Chartmill High Growth Momentum
EPS Q2Q%55.32%
Sales Q2Q%N/A
EPS 1Y (TTM)42.02%
Revenue 1Y (TTM)N/A

RLYB Ownership and Analysts

ChartMill assigns a Buy % Consensus number of 75% to RLYB. The Buy consensus is the average rating of analysts ratings from 11 analysts.

For the next year, analysts expect an EPS growth of 36.16% and a revenue growth -69.46% for RLYB


Ownership
Inst Owners70.58%
Ins Owners2.39%
Short Float %0.9%
Short Ratio1.85
Analysts
Analysts74.55
Price Target1.02 (151.11%)
EPS Next Y36.16%
Revenue Next Year-69.46%